NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi
Conditions: Plasma Cell Myeloma Recurrent
Interventions: Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Dexamethasone
Countries: United States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Participants with multiple myeloma who have received at least one prior line of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor given alone or in combination. * Measurable serum M-protein (≥ 0.5 g/dL) and/or urine M-protein (≥ 200 mg/24 hours) and/or serum free light chain (FLC) assay (Involved FLC assay ≥10 mg/dL and abnormal serum FLC ratio (\<0.26 or \>1.65)). Exclusion Criteria: * Primary refractory multiple myeloma participants * Participants with prior anti-CD38 treatment: (a) administered less than 9 months before randomization or, (b) intolerant to the anti-CD38 previously received * Prior therapy with pomalidomide * Participants with inadequate biological tests. * Significant cardiac dysfunction * Participants diagnosed or treated for another malignancy within 3 years prior to randomization with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low risk prostate cancer after curative therapy * Concomitant plasma cell leukemia * Active primary amyloid light -chain amyloidosis * Known acquired immunodeficiency syndrome (AIDS)-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment * Know active Hepatitis A infection. Current active or chronic hepatitis B (HBV) or hepatitis C (HCV) infection. Participants with chronic HBV or HCV disease that is controlled under antiviral therapy are allowed. * Women of childbearing potential or male participant with women of childbearing potential who do not agree to use highly effective method of birth control The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
- Bullhead City, Arizona, United States
- Prescott Valley, Arizona, United States
- Aurora, Colorado, United States
- Jacksonville, Florida, United States
- Plantation, Florida, United States
- Bethesda, Maryland, United States
- Hattiesburg, Mississippi, United States
- Las Vegas, Nevada, United States
- Morristown, New Jersey, United States
- Albany, New York, United States
- Charlotte, North Carolina, United States
- Winston-Salem, North Carolina, United States
- Canton, Ohio, United States
- Cincinnati, Ohio, United States
- Eugene, Oregon, United States
- Easton, Pennsylvania, United States
- Spartanburg, South Carolina, United States
- Dallas, Texas, United States
- Dallas, Texas, United States
- Kingwood, Texas, United States
- San Antonio, Texas, United States
- Salt Lake City, Utah, United States
- Waukesha, Wisconsin, United States
- CABA, Buenos Aires, Argentina
- CABA, Buenos Aires, Argentina
- Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
- La Plata, Buenos Aires, Argentina
- CABA, Buenos Aires F.D., Argentina
- CABA, Buenos Aires F.D., Argentina
- CABA, Buenos Aires F.D., Argentina
- + 116 more on CT.gov